Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707890 | 1.00 | ELANE (1.00) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL14899925 | 0.93 | ELANE (0.89) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL13872092 | 0.93 | ELANE (0.87) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL13872095 | 0.93 | ELANE (0.87) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL2894512 | 0.92 | ELANE (0.86) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL1764353 | 0.92 | ELANE (1.00) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL3482731 | 0.92 | ELANE (1.00) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL392232 | 0.92 | ELANE (1.00) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL13872877 | 0.92 | ELANE (0.86) | ELANECYP2C9CYP3A4ADRB1HTR1A | |
| SCHEMBL2896569 | 0.91 | ELANE (0.83) | ELANECYP2C9CYP3A4ADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11968891-B2 | Organic electroluminescence device and heterocyclic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-04-23 | — | — | US | disclosed |
| US-11825744-B2 | Organic electroluminescence device and condensed cyclic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| US-11793068-B2 | Amine compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11787822-B2 | Aromatic compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11655211-B2 | Polycyclic compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-3521280-B1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND AMINE COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-05-10 | — | — | EP | disclosed |
| US-11569461-B2 | Organic electroluminescence device and organometallic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-01-31 | — | — | US | disclosed |
| US-11527726-B2 | Organic electroluminescence device and compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-12-13 | — | — | US | disclosed |
| US-11489125-B2 | Organic electroluminescence device and monoamine compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-11-01 | — | — | US | disclosed |
| US-11335860-B2 | Organic electroluminescence device and condensed cyclic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-05-17 | — | — | US | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20100003709-A1 | Crystal Structure of Enzyme and Uses Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| WO-2009057827-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-1828233-A2 | CRYSTAL STRUCTURE OF ENZYME AND USES THEREOF | Bayer HealthCare AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063792-A2 | CRYSTAL STRUCTURE OF ENZYME AND USES THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1546113-A1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | Bayer HealthCare AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004024700-A1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | BAYER HEALTHCARE AG (DE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024700-A1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | BAYER HEALTHCARE AG (DE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787822-B2 | Aromatic compound and organic electroluminescence device including the same | TYR, TOE1, PIEZO1 | ELANE 1823/4885CYP2C9 80/4885CYP3A4 176/4885 |
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | PTGIS, PTGIR, FPR1 | ELANE 59/4885CYP2C9 4171/4885CYP3A4 2835/4885 |
| US-11655211-B2 | Polycyclic compound and organic electroluminescence device including the same | CCNA1, CCNT1, CCNL2 | ELANE 1402/4885CYP2C9 1382/4885CYP3A4 1339/4885 |
| US-11569461-B2 | Organic electroluminescence device and organometallic compound for organic electroluminescence device | CHRM1, L1CAM, CHRM4 | ELANE 1294/4885CYP2C9 2179/4885CYP3A4 857/4885 |
| US-11335860-B2 | Organic electroluminescence device and condensed cyclic compound for organic electroluminescence device | PIEZO1, OCIAD1, AQP1 | ELANE 596/4885CYP2C9 1811/4885CYP3A4 3156/4885 |
| US-11489125-B2 | Organic electroluminescence device and monoamine compound for organic electroluminescence device | MAOA, COMT, PNMT | ELANE 1994/4885CYP2C9 1503/4885CYP3A4 1998/4885 |
| US-11825744-B2 | Organic electroluminescence device and condensed cyclic compound for organic electroluminescence device | PIEZO1, OCIAD1, AQP1 | ELANE 596/4885CYP2C9 1811/4885CYP3A4 3156/4885 |
| US-11968891-B2 | Organic electroluminescence device and heterocyclic compound for organic electroluminescence device | OCIAD1, OCIAD2, SLC25A21 | ELANE 1259/4885CYP2C9 568/4885CYP3A4 441/4885 |
| US-20100003709-A1 | Crystal Structure of Enzyme and Uses Thereof | SERPINB1, ELANE, MMP8 | ELANE 2/4885CYP2C9 1214/4885CYP3A4 830/4885 |
| US-11793068-B2 | Amine compound and organic electroluminescence device including the same | AOC2, H1-2, CHRM1 | ELANE 1842/4885CYP2C9 2371/4885CYP3A4 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.